- Home
- JAZZ
as 02-21-2025 4:00pm EST
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Upcoming Earnings Alert:
Get ready for potential market movements as Jazz Pharmaceuticals plc (Ireland) JAZZ prepares to release earnings report on 25 Feb 2025.
| Founded: | 2003 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN |
| Market Cap: | 8.1B | IPO Year: | 2007 |
| Target Price: | $177.50 | AVG Volume (30 days): | 688.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 7.04 | EPS Growth: | 458.10 |
| 52 Week Low/High: | $99.06 - $138.27 | Next Earning Date: | 02-25-2025 |
| Revenue: | $3,992,712,000 | Revenue Growth: | 5.23% |
| Revenue Growth (this year): | 7.53% | Revenue Growth (next year): | 6.94% |
Stock Insider Trading Activity of Jazz Pharmaceuticals plc (Ireland) (JAZZ)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| COZADD BRUCE C | JAZZ | Chairman & CEO | Feb 3 '25 | Sell | $122.31 | 1,500 | $183,465.00 | 439,744 | |
| COZADD BRUCE C | JAZZ | Chairman & CEO | Jan 2 '25 | Sell | $123.43 | 1,500 | $185,145.00 | 439,744 | |
| COZADD BRUCE C | JAZZ | Chairman & CEO | Dec 2 '24 | Sell | $121.17 | 2,000 | $242,340.00 | 439,744 | |
| Carr Patricia | JAZZ | SVP, Chief Accounting Officer | Dec 2 '24 | Sell | $122.49 | 53 | $6,491.97 | 6,596 |
Latest Jazz Pharmaceuticals plc (Ireland) News
JAZZ Breaking Stock News: Dive into JAZZ Ticker-Specific Updates for Smart Investing
PR Newswire
a day ago
Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
Zacks
a day ago
Jazz (JAZZ) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Argus Research
3 days ago
JAZZ: Raising target price to $149.00
Zacks
9 days ago
Jazz (JAZZ) Surges 5.2%: Is This an Indication of Further Gains?
PR Newswire
10 days ago
Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
Zacks
16 days ago
Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again
Argus Research
17 days ago
JAZZ: Lowering target price to $134.00
Argus Research
24 days ago
JAZZ: Raising target price to $136.00
Compare JAZZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JAZZ Jazz Pharmaceuticals plc (Ireland) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.